EP3666776A1 — Hydrate of a gonadotropin-releasing hormone receptor antagonist
Assigned to Sandoz AG · Expires 2020-06-17 · 6y expired
What this patent protects
The present invention relates to relugolixhemihydrate and a process for its preparation. The invention also relates to a pharmaceutical composition comprising relugolixhemihydrate, preferably in a predetermined and/or effective amount and at least one pharmaceutically acceptable …
USPTO Abstract
The present invention relates to relugolixhemihydrate and a process for its preparation. The invention also relates to a pharmaceutical composition comprising relugolixhemihydrate, preferably in a predetermined and/or effective amount and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of a condition selected from the group consisting of endometriosis, uterine fibroids and prostate cancer.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.